52,000 Shares in Immunome, Inc. $IMNM Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new position in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 52,000 shares of the company’s stock, valued at approximately $1,123,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Immunome in the fourth quarter worth approximately $64,000. Assetmark Inc. acquired a new position in Immunome in the third quarter worth approximately $39,000. BIT Capital GmbH acquired a new position in Immunome in the third quarter worth approximately $69,000. BNP Paribas Financial Markets increased its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Immunome in the third quarter worth approximately $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Down 1.3%

IMNM opened at $18.16 on Thursday. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -7.63 and a beta of 2.04. The business has a 50 day moving average of $21.92 and a 200-day moving average of $21.71.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. Equities analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

IMNM has been the topic of a number of research reports. Stephens dropped their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Craig Hallum upped their target price on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Barclays initiated coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Finally, Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime bought 10,500 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average cost of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the purchase, the director owned 43,415 shares of the company’s stock, valued at $844,421.75. This trade represents a 31.90% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Philip Wagenheim sold 28,200 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the completion of the transaction, the director owned 341,147 shares of the company’s stock, valued at $7,044,685.55. The trade was a 7.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 over the last ninety days. 7.21% of the stock is owned by insiders.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.